期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
一批治疗心脑血管疾病新药
1
作者 徐荣周 《医药导报》 CAS 1994年第2期66-67,共2页
1 博洛克 博洛克以人工培养的一种特殊蚯蚓为原料,采用现代生化科学分离技术精制而成,其产品质量含量均高于国内外水平。经临床研究结果证明,此药对于治疗缺血性脑血管病总有效率达93.73%,显效率73.60%.该产品已由南昌江中制药厂生产... 1 博洛克 博洛克以人工培养的一种特殊蚯蚓为原料,采用现代生化科学分离技术精制而成,其产品质量含量均高于国内外水平。经临床研究结果证明,此药对于治疗缺血性脑血管病总有效率达93.73%,显效率73.60%.该产品已由南昌江中制药厂生产,投放市场。 2 黄杨宁片 黄杨宁片是从天然植物中提炼精制而成。用于治疗冠心病、心绞痛、心肌梗塞、心律不齐、心功能不全,对高低血压有双向调节作用,通过血脑屏障,改善微循环,对脑血栓脑供氧不足,疗效较好,副作用小等特点。该药是南京小营制药厂独家生产的新产品,曾荣获国家优秀新产品奖、国家发明奖和全军重大科技成果奖。 3 展开更多
关键词 心血管疾病药 治疗应用
在线阅读 下载PDF
康可临床治疗有效剂量与心率变化的相关性
2
作者 徐金和 罗佛贤 桂维成 《医药导报》 CAS 1993年第4期197-199,共3页
康可的临床治疗有效剂量均有减慢心率的副作用。其治疗剂量与心率减慢之间呈明显的正相关。但其减慢后的稳定心率仍在正常范围内,是一种无症状性的心率减慢。所以,康可在治疗高血压、冠心病、心绞痛及心律失常时的有效剂量是安全的。
关键词 康可 心率变化 心血管疾病药
在线阅读 下载PDF
THBS4 in Disease:Mechanisms,Biomarkers,and Therapeutic Opportunities
3
作者 HUANG De-Ying LI Yan-Hong +1 位作者 BAI Xiu-Feng LIU Yi 《生物化学与生物物理进展》 2025年第9期2217-2232,共16页
Thrombospondin 4(THBS4;TSP4),a crucial component of the extracellular matrix(ECM),serves as an important regulator of tissue homeostasis and various pathophysiological processes.As a member of the evolutionarily conse... Thrombospondin 4(THBS4;TSP4),a crucial component of the extracellular matrix(ECM),serves as an important regulator of tissue homeostasis and various pathophysiological processes.As a member of the evolutionarily conserved thrombospondin family,THBS4 is a multidomain adhesive glycoprotein characterized by six distinct structural domains that mediate its diverse biological functions.Through dynamic interactions with various ECM components,THBS4 plays pivotal roles in cell adhesion,proliferation,inflammation regulation,and tissue remodeling,establishing it as a key modulator of microenvironmental organization.The transcription and translation of THBS4 gene,as well as the activity of the THBS4 protein,are tightly regulated by multiple signaling pathways and extracellular cues.Positive regulators of THBS4 include transforming growth factorβ(TGF-β),interferonγ(IFNγ),granulocyte-macrophage colony-stimulating factor(GM-CSF),bone morphogenetic proteins(BMP12/13),and other regulatory factors(such as B4GALNT1,ITGA2/ITGB1,PDGFRβ,etc.),which upregulate THBS4 at the mRNA and/or protein level.Conversely,oxidized low-density lipoprotein(OXLDL)acts as a potent negative regulator of THBS4.This intricate regulatory network ensures precise spatial and temporal control of THBS4 expression in response to diverse physiological and pathological stimuli.Functionally,THBS4 acts as a critical signaling hub,influencing multiple downstream pathways essential for cellular behavior and tissue homeostasis.The best-characterized pathways include:(1)the PI3K/AKT/mTOR axis,which THBS4 modulates through both direct and indirect interactions with integrins and growth factor receptors;(2)Wnt/β-catenin signaling,where THBS4 functions as either an activator or inhibitor depending on the cellular context;(3)the suppression of DBET/TRIM69,contributing to its diverse regulatory roles.These signaling connections position THBS4 as a master regulator of cellular responses to microenvironmental changes.Substantial evidence links aberrant THBS4 expression to a range of pathological conditions,including neoplastic diseases,cardiovascular disorders,fibrotic conditions,neurodegenerative diseases,musculoskeletal disorders,and atopic dermatitis.In cancer biology,THBS4 exhibits context-dependent roles,functioning either as a tumor suppressor or promoter depending on the tumor type and microenvironment.In the cardiovascular system,THBS4 contributes to both adaptive remodeling and maladaptive fibrotic responses.Its involvement in fibrotic diseases arises from its ability to regulate ECM deposition and turnover.The diagnostic and therapeutic potential of THBS4 is particularly promising in oncology and cardiovascular medicine.As a biomarker,THBS4 expression patterns correlate significantly with disease progression and patient outcomes.Therapeutically,targeting THBS4-mediated pathways offers novel opportunities for precision medicine approaches,including anti-fibrotic therapies,modulation of the tumor microenvironment,and enhancement of tissue repair.This comprehensive review systematically explores three key aspects of THBS4 research:(1)the fundamental biological functions of THBS4 in ECM organization;(2)its mechanistic involvement in various disease pathologies;(3)its emerging potential as both a diagnostic biomarker and therapeutic target.By integrating recent insights from molecular studies,animal models,and clinical investigations,this review provides a framework for understanding the multifaceted roles of THBS4 in health and disease.The synthesis of current knowledge highlights critical research gaps and future directions for exploring THBS4-targeted interventions across multiple disease contexts.Given its unique position at the intersection of ECM biology and cellular signaling,THBS4 represents a promising frontier for the development of novel diagnostic tools and therapeutic strategies in precision medicine. 展开更多
关键词 thrombospondin 4 cancers cardiovascular diseases fibrotic diseases targeted pharmacological
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部